CLINICAL_TRIALS
trial_result
· 2021-05-11
Clinical Trial Update: BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder [Phase 2]
Summary
Phase 2 trial assessing once-daily BTRX-246040 in patients with major depressive disorder has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: BlackThorn Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2021-05-11